Floatz logo

Tazemetostat

Hemophagocytic Lymphohistiocytosis (HLH)

Beijing Tongren HospitalSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Hemophagocytic Lymphohistiocytosis (HLH) cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
Baylor College of Medicine
Phase 2B
Campath-1H
Baylor College of Medicine
Phase 2CCC
Mitoxantrone
Beijing Tongren Hospital
Phase 1/2CC
Golidocitinib
Beijing Tongren Hospital
Phase 1/2CC

Same molecule, other indications

Tazemetostat is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
epithelioid sarcomaDormant
BB
Indicative ·
70 / 100
View asset →
kidney medullary carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →